Neonatal screening for sickle cell disease in France: Evaluation of the selective process

Journal of Clinical Pathology

Volumn 63, Issue 6, 2010, Pages 548-551

  Thuret, Isabelle ^a   Sarles, Jacques ^a   Merono, Françoise ^b   Suzineau, Eliane ^c   Collomb, Jacques ^c   Lena Russo, Danielle ^b   Levy, Nicolas ^a,b   Bardakdjian, Josiane ^d   Badens, Catherine ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Service de Lutte Contre la Tuberculose   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; DIAGNOSTIC ERROR; FRANCE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; FALSE NEGATIVE REACTIONS; FEASIBILITY STUDIES; FRANCE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PATIENT SELECTION; PROGRAM EVALUATION; RETROSPECTIVE STUDIES;

EID: 77953704275     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.068874     Document Type: Article

References (14)

1. Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988;81:749-55.
2. Lena-Russo D, Bardakdjian-Michau J. Le dépistage néonatal in Girot R, La drépanocytose. Paris: John Libbey Eurotext, 2003:287-91.
3. Bardakdjian-Michau J, Bahuau M, Hurtrel D, et al. Neonatal screening for sickle cell disease in France. J Clin Pathol 2009;62:31-3.
4. Benkerrou M, Badens C, Bardakdjian-Michau J, et al. Le dépistage néonatal ciblé de la drépanocytose en France Métropolitaine: raisons et résultats. mt pédiatrie 2002;5:159-63.
5. Tsevat J, Wong JB, Pauker SG, et al. Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr 1999;118:546-54.
6. Panepinto JA, Magid D, Rewers MJ, et al. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000;136:201-8.
7. Sprinkle RH, Hynes DM, Konrad TR. Is universal neonatal hemoglobinopathy screening cost-effective? Arch Pediatr Adolesc Med 1994;148:461-9.
8. Gessner BD, Teutsch SM, Shaffer PA. A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems. Early Hum Dev 1996;45:257-75.
9. Cronin EK, Normand C, Henthorn JS, et al. Costing model for neonatal screening and diagnosis of haemoglobinopathies. Arch Dis Child Fetal Neonatal Ed 1998;79:F161-7.
10. Aspinall PJ, Dyson SM, Anionwu EN. The feasibility of using ethnicity as a primary tool for antenatal selective screening for sickle cell disorders: pointers from the research evidence. Soc Sci Med 2003;56:285-97.
11. Munck A, Dhondt JL, Sahler C, et al. Implementation of the French nationwide cystic fibrosis newborn screening program. J Pediatr 2008;153:228-33.
12. Kempers MJ, Lanting CI, van Heijst AF, et al. Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin measurement: potentials and pitfalls. J Clin Endocrinol Metab 2006;91:3370-6.
13. Schreiner F, Brack C, Salzgeber K, et al. False negative 17-hydroxyprogesterone screening in children with classical congenital adrenal hyperplasia. Eur J Pediatr 2008;167:479-81.
14. Githens JH, Lane PA, McCurdy RS, et al. Newborn screening for hemoglobinopathies in Colorado. The first 10 years. Am J Dis Child 1990;144:466-70.